Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan. Blakkisrud, J., Løndalen, A., Martinsen, A. C., Dahle, J., Holtedahl, J. E, Bach-Gansmo, T., Holte, H., Kolstad, A., & Stokke, C. Journal of Nuclear Medicine, 58(1):48–54, Soc Nuclear Med, 2017.
doi  bibtex   
@article{blakkisrud2017tumor,
  title={Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan},
  author={Blakkisrud, Johan and L{ø}ndalen, Ayca and Martinsen, Anne CT and Dahle, Jostein and Holtedahl, Jon E and Bach-Gansmo, Tore and Holte, Harald and Kolstad, Arne and Stokke, Caroline},
  journal={Journal of Nuclear Medicine},
  volume={58},
  number={1},
  pages={48--54},
  year={2017},
  publisher={Soc Nuclear Med},
  doi={10.2967/jnumed.116.173922}
}

Downloads: 0